Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 357-360 , October 2004

Pharmacokinetics of estrogen and progesterone in chronic kidney disease

  • Gail D. Anderson

      Affiliations

    • Department of Pharmacy, University of Washington, Seattle, WA, USA
    • Corresponding Author InformationAddress correspondence to Gail D. Anderson, PhD, Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195
    • ,
  • Peggy S. Odegard

      Affiliations

    • Department of Pharmacy, University of Washington, Seattle, WA, USA

References 

  1. Longcope C , Jaffee W , Griffing G . Metabolic clearance rates of androgens and oestrogens in ageing women . Maturitas . 1980;2:283–290
  2. Aedo AR , Sunden M , Landgren BM , et al.   Effect of orally administered oestrogens on circulating oestrogen profiles in post-menopausal women . Maturitas . 1989;11:159–168
  3. Grow DR . Metabolism of endogenous and exogenous reproductive hormones . Obstet Gynecol Clin North Am . 2002;29:425–436
  4. Nichols KC , Schenkel L , Benson H . 17 beta-estradiol for postmenopausal estrogen replacement therapy . Obstet Gynecol Surv . 1984;39:230–245
  5. Longcope C , Williams KI . The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone . J Clin Endocrinol Metab . 1974;38:602–607
  6. Kuhnz W , Gansau C , Mahler M . Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol . Arzneimittelforschung . 1993;43:966–973
  7. O’Connell MB . Pharmacokinetic and pharmacologic variation between different estrogen products . J Clin Pharmacol . 1995;35(suppl):18S–24S
  8. Henzl MR , Loomba PK . Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice . J Reprod Med . 2003;48:525–540
  9. Setnikar I , Rovati LC , Santoro A , et al.   Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch . Arzneimittelforschung . 1999;49:708–715
  10. Ginsburg ES , Gao X , Shea BF , et al.   Half-life of estradiol in postmenopausal women . Gynecol Obstet Invest . 1998;45:45–48
  11. Bhavnani BR . Pharmacokinetics and pharmacodynamics of conjugated equine estrogens (Chemistry and metabolism) . Proc Soc Exp Biol Med . 1998;217:6–16
  12. Greendale GA , Judd HL . The menopause (Health implications and clinical management) . J Am Geriatr Soc . 1993;41:426–436
  13. Aedo AR , Landgren BM , Cekan Z , et al.   Studies on the pattern of circulating steroids in the normal menstrual cycle. 2. Levels of 20alpha-dihydroprogesterone, 17-hydroxy-progesterone and 17-hydroxypregnenolone and the assessment of their value for ovulation prediction . Acta Endocrinol (Copenh) . 1976;82:600–616
  14. Kuhl H . Pharmacokinetics of oestrogens and progestogens . Maturitas . 1990;12:171–197
  15. de Lignieres B . Oral micronized progesterone . Clin Ther . 1999;21:41–60
  16. McAuley JW , Kroboth FJ , Kroboth PD . Oral administration of micronized progesterone (A review and more experience) . Pharmacotherapy . 1996;16:453–457
  17. Victor A , Johansson ED . Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginally . Contraception . 1976;14:319–329
  18. Ginsburg ES , Owen WF , Greenberg LM , et al.   Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease . J Clin Endocrinol Metab . 1996;81:4414–4417
  19. van Kammen E , Thijssen JH , Donker GH , et al.   The excretion of metabolites of testosterone and of estradiol in male patients with chronic renal failure . Steroids . 1975;26:508–515
  20. Stehman-Breen C , Anderson G , Gibson D , et al.   Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis . Kidney Int . 2003;64:290–294
  21. Matuszkiewicz-Rowinska J , Skorzewska K , Radowicki S , et al.   The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis . Nephrol Dial Transplant . 1999;14:1238–1243
  22. Ylikorkala O , Cacciatore B , Paakkari I , et al.   The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane . Fertil Steril . 1998;69:883–888
  23. Dada OA , Laumas V , Landgren BM , et al.   Effect of graded oral doses of oestradiol on circulating hormonal levels . Acta Endocrinol (Copenh) . 1978;88:754–767
  24. Whittaker PG , Morgan MR , Dean PD , et al.   Serum equilin, oestrone, and oestradiol levels in postmenopausal women receiving conjugated equine oestrogens (‘Premarin’) . Lancet . 1980;1:14–16
  25. Studd J , Savvas M , Waston N , et al.   The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants . Am J Obstet Gynecol . 1990;163:1474–1479
  26. Armston A , Wood P . Hormone replacement therapy (oestradiol-only preparations) (can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?) . Ann Clin Biochem . 2002;39:184–193
  27. Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women . JAMA . 1995;273:199–220

PII: S1548-5595(04)00114-4

doi: 10.1053/j.ackd.2004.07.001

Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 357-360 , October 2004

Article Tools